YORHAVYN Trademark
YORHAVYN is a USPTO trademark filed by CSL Behring GmbH. Status: Registered.
Trademark Facts
| Mark | YORHAVYN |
|---|---|
| Serial Number | 97777748 |
| Registration Number | 7877491 |
| Status | Registered |
| Filing Date | 2023-02-02 |
| Registration Date | 2025-08-05 |
| Mark Type | Word |
| Nice Classes | 005 (Pharmaceuticals) |
| Owner | CSL Behring GmbH |
| Attorney of Record | SCOTT D. WOLDOW |
| Prosecution Events | 22 |
| Latest Event | NRCC on 2025-08-05 |
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes in the hematology field; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing in the hematology field; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use in the hematology field; cell cultures for medical purposes, namely, living cells for medical use in the hematology field; cell cultures for medical purposes, namely, stem cells for medical or veterinary use in the hematology field; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE